Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9)

Jonathan I. Silverberg; Jacob P. Thyssen; Eric L. Simpson; Gil Yosipovitch; Sonja Ständer; Hernan Valdez; Ricardo Rojo; Pinaki Biswas; Daniela E. Myers; Claire Feeney; Marco DiBonaventura

doi:10.1007/s40257-021-00634-3

Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9)

Jonathan I. Silverberg, Jacob P. Thyssen, Eric L. Simpson, Gil Yosipovitch, Sonja Ständer, Hernan Valdez, Ricardo Rojo, Pinaki Biswas, Daniela E. Myers, Claire Feeney, Marco DiBonaventura

Dermatology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)^a and b Children’s Dermatology Life Quality Index (CDLQI)^b band descriptors. ^aFor patients ≥ 8 years of age. ^bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)^a and b Children’s Dermatology Life Quality Index (CDLQI)^b band descriptors. ^aFor patients ≥ 18 years of age. ^bFor patients < 18 years of age.

Original language	English (US)
Pages (from-to)	739
Number of pages	1
Journal	American Journal of Clinical Dermatology
Volume	22
Issue number	5
DOIs	https://doi.org/10.1007/s40257-021-00634-3
State	Published - Sep 2021

ASJC Scopus subject areas

Dermatology

Access to Document

10.1007/s40257-021-00634-3

Fingerprint

Dive into the research topics of 'Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9)'. Together they form a unique fingerprint.

Cite this

Silverberg, J. I., Thyssen, J. P., Simpson, E. L., Yosipovitch, G., Ständer, S., Valdez, H., Rojo, R., Biswas, P., Myers, D. E., Feeney, C., & DiBonaventura, M. (2021). Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9). American Journal of Clinical Dermatology, 22(5), 739. https://doi.org/10.1007/s40257-021-00634-3

Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9). / Silverberg, Jonathan I.; Thyssen, Jacob P.; Simpson, Eric L. et al.
In: American Journal of Clinical Dermatology, Vol. 22, No. 5, 09.2021, p. 739.

Research output: Contribution to journal › Comment/debate › peer-review

Silverberg, JI, Thyssen, JP, Simpson, EL, Yosipovitch, G, Ständer, S, Valdez, H, Rojo, R, Biswas, P, Myers, DE, Feeney, C & DiBonaventura, M 2021, 'Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9)', American Journal of Clinical Dermatology, vol. 22, no. 5, pp. 739. https://doi.org/10.1007/s40257-021-00634-3

Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Ständer S, Valdez H et al. Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9). American Journal of Clinical Dermatology. 2021 Sep;22(5):739. doi: 10.1007/s40257-021-00634-3

Silverberg, Jonathan I. ; Thyssen, Jacob P. ; Simpson, Eric L. et al. / Correction to : Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9). In: American Journal of Clinical Dermatology. 2021 ; Vol. 22, No. 5. pp. 739.

@article{104220d590124d1192e0ea66049069e7,

title = "Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9)",

abstract = "Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)a and b Children{\textquoteright}s Dermatology Life Quality Index (CDLQI)b band descriptors. aFor patients ≥ 8 years of age. bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)a and b Children{\textquoteright}s Dermatology Life Quality Index (CDLQI)b band descriptors. aFor patients ≥ 18 years of age. bFor patients < 18 years of age.",

author = "Silverberg, {Jonathan I.} and Thyssen, {Jacob P.} and Simpson, {Eric L.} and Gil Yosipovitch and Sonja St{\"a}nder and Hernan Valdez and Ricardo Rojo and Pinaki Biswas and Myers, {Daniela E.} and Claire Feeney and Marco DiBonaventura",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Nature Switzerland AG.",

year = "2021",

month = sep,

doi = "10.1007/s40257-021-00634-3",

language = "English (US)",

volume = "22",

pages = "739",

journal = "American Journal of Clinical Dermatology",

issn = "1175-0561",

publisher = "Adis International Ltd",

number = "5",

}

TY - JOUR

T1 - Correction to

T2 - Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes (American Journal of Clinical Dermatology, (2021), 22, 4, (541-554), 10.1007/s40257-021-00604-9)

AU - Silverberg, Jonathan I.

AU - Thyssen, Jacob P.

AU - Simpson, Eric L.

AU - Yosipovitch, Gil

AU - Ständer, Sonja

AU - Valdez, Hernan

AU - Rojo, Ricardo

AU - Biswas, Pinaki

AU - Myers, Daniela E.

AU - Feeney, Claire

AU - DiBonaventura, Marco

PY - 2021/9

Y1 - 2021/9

N2 - Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)a and b Children’s Dermatology Life Quality Index (CDLQI)b band descriptors. aFor patients ≥ 8 years of age. bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)a and b Children’s Dermatology Life Quality Index (CDLQI)b band descriptors. aFor patients ≥ 18 years of age. bFor patients < 18 years of age.

AB - Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)a and b Children’s Dermatology Life Quality Index (CDLQI)b band descriptors. aFor patients ≥ 8 years of age. bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI)a and b Children’s Dermatology Life Quality Index (CDLQI)b band descriptors. aFor patients ≥ 18 years of age. bFor patients < 18 years of age.

UR - http://www.scopus.com/inward/record.url?scp=85112825822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112825822&partnerID=8YFLogxK

U2 - 10.1007/s40257-021-00634-3

DO - 10.1007/s40257-021-00634-3

M3 - Comment/debate

C2 - 34406620

AN - SCOPUS:85112825822

SN - 1175-0561

VL - 22

SP - 739

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

IS - 5

ER -

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this